Last reviewed · How we verify

Hyperbaric Bupivicaine

University of Witwatersrand, South Africa · FDA-approved active Small molecule Under review Quality 0/100

Hyperbaric Bupivicaine is a Local anesthetic (amide) Small molecule drug developed by University of Witwatersrand, South Africa. It is currently FDA-approved for Spinal anesthesia for surgical procedures, Regional anesthesia and analgesia. Also known as: Spinal Bupivicaine, Bupivacaine, hyperbaric bupivacaine.

Hyperbaric bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce regional anesthesia.

Hyperbaric Bupivacaine is a small molecule that acts as a sodium channel protein type IV alpha subunit blocker, classified as a blocker. It is used in subarachnoid anesthesia for conditions such as hip fracture and postoperative complications, often in combination with other agents like dexmedetomidine.

At a glance

Generic nameHyperbaric Bupivicaine
Also known asSpinal Bupivicaine, Bupivacaine, hyperbaric bupivacaine
SponsorUniversity of Witwatersrand, South Africa
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx into nerve fibers, thereby preventing depolarization and nerve impulse transmission. The hyperbaric formulation (made hypertonic with dextrose) increases the density of the solution, allowing it to settle dependently in the cerebrospinal fluid when used for spinal anesthesia, providing predictable distribution and duration of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hyperbaric Bupivicaine

What is Hyperbaric Bupivicaine?

Hyperbaric Bupivicaine is a Local anesthetic (amide) drug developed by University of Witwatersrand, South Africa, indicated for Spinal anesthesia for surgical procedures, Regional anesthesia and analgesia.

How does Hyperbaric Bupivicaine work?

Hyperbaric bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce regional anesthesia.

What is Hyperbaric Bupivicaine used for?

Hyperbaric Bupivicaine is indicated for Spinal anesthesia for surgical procedures, Regional anesthesia and analgesia.

Who makes Hyperbaric Bupivicaine?

Hyperbaric Bupivicaine is developed and marketed by University of Witwatersrand, South Africa (see full University of Witwatersrand, South Africa pipeline at /company/university-of-witwatersrand-south-africa).

Is Hyperbaric Bupivicaine also known as anything else?

Hyperbaric Bupivicaine is also known as Spinal Bupivicaine, Bupivacaine, hyperbaric bupivacaine.

What drug class is Hyperbaric Bupivicaine in?

Hyperbaric Bupivicaine belongs to the Local anesthetic (amide) class. See all Local anesthetic (amide) drugs at /class/local-anesthetic-amide.

What development phase is Hyperbaric Bupivicaine in?

Hyperbaric Bupivicaine is FDA-approved (marketed).

What are the side effects of Hyperbaric Bupivicaine?

Common side effects of Hyperbaric Bupivicaine include Hypotension, Bradycardia, Headache (post-dural puncture), Neurological toxicity (at high doses), Cardiovascular toxicity (at high doses).

What does Hyperbaric Bupivicaine target?

Hyperbaric Bupivicaine targets Voltage-gated sodium channels and is a Local anesthetic (amide).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing